Clinical Trial

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-16.
Status change: Not Yet Recruiting → Recruiting 2025-09-18
Trial Details
NCT Number NCT06838208
Lead Sponsor Anhui Provincial Cancer Hospital
Conditions Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Enrollment 56 participants
Start Date 2025-02-25
Primary Completion 2027-03-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-24